Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 49 от 100

Набира участници

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Non-Small Cell Lung Cancer

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

Начало: 02.03.2026 Край: 31.07.2026 Възраст: от 18 г.

China AstraZeneca NCT07413757

Набира участници Фаза 1

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Hearing Loss Metastatic Malignant Germ Cell Tumor Metastatic Malignant Nongerminomatous Germ Cell Tumor Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor +3

This phase I trial evaluates whether adding Pedmark to standard of care cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with stage II-III testicular germ cell tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Cisplatin-induced ototoxicity remains a major concern in adult patients with germ cell tumors as nearly four out of five patients develop hearing loss after treatment. Cisplatin is thought to cause ear damage by the production of chemically reactive molecules called reactive oxygen species. These molecules can cause damage when their levels get too high. Pedmark may reduce the negative side effects of cisplatin by neutralizing these reactive molecules. Pedmark has been approved for reducing the risk of cisplatin-induced ototoxicity in pediatric patients and older patients with solid tumors that haven't spread to other parts of the body. Adding Pedmark to cisplatin-based chemotherapy treatment may reduce ototoxicity in adult men with stage I-III testicular metastatic germ cell tumors.

Начало: 19.02.2026 Край: 22.01.2031 Възраст: от 18 г.

United States City of Hope Medical Center NCT07218913

Набира участници

Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

Breast Carcinoma Breast Cancer

This study compares measurements of body composition to outcomes of breast reconstruction.

Начало: 18.02.2026 Край: 31.12.2028 Възраст: от 18 г.

United States University of California, San Francisco NCT07546331

Набира участници Фаза 2

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharangeal Cancer

In this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies/ml, AJCC 9th edition) that is sensitive to chemotherapy and PD-1 monoclonal antibody therapy. The trial compares sequential treatment with the TP regimen combined with PD-1 monoclonal antibody followed by concurrent chemoradiotherapy and PD-1 maintenance therapy versus capecitabine maintenance therapy. The aim is to provide high-quality clinical evidence for optimizing the treatment strategy for high-risk locally advanced nasopharyngeal carcinoma.

Начало: 10.02.2026 Край: 10.02.2033 Възраст: 18–70 г.

China Sun Yat-sen University NCT07392320

Набира участници Фаза 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Gastric Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Cancer

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Начало: 03.02.2026 Край: 27.10.2031 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +18 AstraZeneca NCT07431281

Набира участници Фаза 1

A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors

Cancer

Evaluate the initial dose-effect and time-effect relationship of the injection product NC527-X

Начало: 24.12.2025 Край: 30.06.2027 Възраст: от 18 г.

China Zhejiang Cancer Hospital NCT07538648

Набира участници Фаза 1/2

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Melanoma (Skin) Non Small Cell Lung Cancer Breast Cancer

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.

Начало: 17.12.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia, United States Hummingbird Bioscience NCT06956690

Набира участници Фаза 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-Small-Cell Lung Cancer Metastatic Non-Small-Cell Lung Cancer Advanced Non-Small-Cell Lung Cancer EGFR P-Loop and Alpha C-Helix Compressing +2

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.

Начало: 17.12.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Canada, Greece +10 ArriVent BioPharma, Inc. NCT07185997

Набира участници Фаза 1

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Advanced Cancers

This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.

Начало: 16.12.2025 Край: 01.12.2028 Възраст: 18–75 г.

China Shanghai Chia Tai Tianqing Pharmaceutical Technology De NCT07260708

Набира участници

B.Brilliant Revelation Comparision Study

Breast Cancer Screening

This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices

Начало: 15.12.2025 Край: 30.01.2027 Възраст: от 18 г.

United States University of Pennsylvania NCT07067788

Набира участници Фаза 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Gastric Cancer MSI-H Metastatic Cancer Advanced Cancer

CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).

Начало: 08.12.2025 Край: 15.05.2028 Възраст: от 18 г.

France Centre Leon Berard NCT06346197

Набира участници Фаза 1

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Pancreatic Ductal Adenocarcinoma Non-Small Cell Lung Cancer HR+/HER2- Ductal and Lobular Breast Cancer Triple Negative Breast Cancer +2

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Начало: 24.11.2025 Край: 09.05.2029 Възраст: 18–100 г.

Canada, Denmark, France +2 Novartis Pharmaceuticals NCT07261631

Набира участници Фаза 1/2

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Advanced Solid Cancers

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.

Начало: 18.11.2025 Край: 01.05.2030 Възраст: от 18 г.

Germany, Spain, United Kingdom +1 BioNTech SE NCT07186842

Набира участници Фаза 1/2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Prostate Cancers Breast Cancer Lung Cancers Ovarian Cancer +3

This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.

Начало: 07.11.2025 Край: 26.10.2027 Възраст: от 18 г. Лечение

Australia Filamon LTD NCT06926075

Набира участници

CAIX PET/ CT Guided Radiation Therapy in CcRCC.

Radiation Therapy Metastatic Renal Cancer Recurrent Renal Cell Cancer

This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \~70).

Начало: 01.11.2025 Край: 31.12.2030 Възраст: от 18 г.

China Peking University First Hospital NCT07540260

Набира участници Фаза 1

PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.

Liver Cancer

Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy

Начало: 23.10.2025 Край: 30.12.2026 Възраст: 18–70 г.

China West China Hospital NCT07053072

Набира участници

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Breast Cancer

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Начало: 15.10.2025 Край: 30.12.2029 Възраст: от 19 г.

South Korea AstraZeneca NCT06927648

Набира участници Фаза 2

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Metastatic Non-Squamous Non-Small Cell Lung Cancer Adult Solid Tumor

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Начало: 07.10.2025 Край: 01.10.2031 Възраст: от 18 г.

Germany, Italy, Spain +2 CatalYm GmbH NCT07246863

Набира участници Фаза 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Metastatic Castration Sensitive Prostate Cancer (mCSPC) Hormone Sensitive Prostate Cancer Prostate Cancer Cancer of the Prostate

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

Начало: 28.09.2025 Край: 08.12.2034 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Pfizer NCT07028853

Набира участници Фаза 1

A Study of PHN-012 in Patients With Advanced Solid Tumors

Colon Cancer Pancreatic Cancer Lung Cancer (NSCLC) Advanced Cancer +1

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Начало: 23.09.2025 Край: 01.05.2028 Възраст: от 18 г.

Spain, United States Pheon Therapeutics NCT07127874

1 … 47 48 49 50 51 … 100